Eli Lilly Income Statement $LLY (+0,39 %)

$LLY Eli Lilly Q2 FY24:

Mounjaro, Zepbound, and Verzenio drive growth.

• Revenue +36% Y/Y to $11.3B ($1.3B beat).

• EPS $3.92 ($1.16 beat).

FY24 guidance (high end):

• Revenue +$3.0B to $46.6B.

• EPS +$0.29 to $14.00.